抗骨吸收治疗与肩关节置换发生率降低相关
本研究利用TriNetX数据库,评估骨质疏松药物治疗对肩骨关节炎进展的影响,以全肩关节置换术(TSA)发生率为代理指标。经倾向性评分匹配后,接受抗骨吸收治疗(地舒单抗或双膦酸盐)的患者5年TSA发生率低于未治疗对照组(1.80% vs 2.60%,p=0.014),Kaplan-Meier分析证实风险降低(HR 0.69,95%CI 0.52-0.93)。地舒单抗与双膦酸盐之间无显著差异。
要点
- 抗骨吸收治疗与肩骨关节炎患者5年TSA发生率降低相关(1.80% vs 2.60%,p=0.014)。
- Kaplan-Meier分析显示抗骨吸收治疗组TSA风险显著降低(HR 0.69,95%CI 0.52-0.93)。
- 地舒单抗与双膦酸盐在5年TSA发生率上无显著差异(1.8% vs 1.4%,p=0.561)。
核心结论
- 在肩骨关节炎合并骨质疏松患者中,抗骨吸收药物治疗与5年全肩关节置换术发生率降低相关。
- 地舒单抗与双膦酸盐两种抗骨吸收药物之间,5年TSA发生率无显著差异。
研究设计与样本
- 基于TriNetX数据库的回顾性队列研究。
- 纳入诊断为原发性肩骨关节炎的骨质疏松患者,经1:1倾向性评分匹配控制相关合并症,形成抗骨吸收治疗组(地舒单抗或双膦酸盐)与未治疗对照组,每组n=4,163。
- 亚组分析比较地舒单抗与双膦酸盐,经类似匹配后每组n=844。
- 主要结局为5年TSA发生率及无TSA生存率,显著性水平设定为p<0.05。
主要发现
- 抗骨吸收治疗组与未治疗对照组5年TSA发生率分别为1.80%与2.60%(p=0.014)。
- Kaplan-Meier生存分析显示抗骨吸收治疗组TSA风险比为0.69(95%CI 0.52-0.93)。
- 地舒单抗与双膦酸盐组5年TSA发生率分别为1.8%与1.4%(p=0.561)。
- 地舒单抗与双膦酸盐组Kaplan-Meier分析风险比为1.25(95%CI 0.58-2.67)。
临床怎么用
- 对于肩骨关节炎合并骨质疏松的患者,抗骨吸收治疗可能有助于延缓骨关节炎进展、降低全肩关节置换术需求。
- 地舒单抗与双膦酸盐在降低TSA发生率方面未见显著差异,药物选择可综合考虑其他因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE: Evaluate whether osteoporosis treatment influences osteoarthritis (OA) progression, using total shoulder arthroplasty (TSA) incidence as a proxy. MAIN RESULT: Osteoporosis treatment was associated with lower TSA incidence compared with untreated patients. SIGNIFICANCE: Findings may clarify the relationship between osteoporosis management and shoulder OA progression, informing patient counseling and management. PURPOSE: We evaluated in this study the impact of osteoporosis (OP) medications in patients with shoulder osteoarthritis (OA) and compared the incidence of total shoulder arthroplasty (TSA) in treated versus untreated OP patients. We hypothesized that OP medications would lead to a decreased progression of OA, manifesting as a decreased incidence of TSA. METHODS: Using the TriNetX database, patients with OP diagnosed with primary shoulder OA were identified. Propensity score matching (1:1) was performed to control for relevant comorbidities, creating two cohorts of patients receiving antiresorptive therapy (denosumab or bisphosphonates) and untreated OP controls (n = 4,163 per group). A sub-analysis was conducted using similarly matched cohorts comparing denosumab versus bisphosphonates (n = 844 per group). The outcome of interest was the 5-year incidence of TSA in addition to TSA-free survival. Significance was set at p < 0.05. RESULTS: The matched cohorts in both analyses were properly balanced. Patients receiving antiresorptive therapy demonstrated a lower 5-year incidence of TSA compared with untreated controls (1.80% vs 2.60%, p = 0.014), which was confirmed on Kaplan-Meier survival analysis (Hazard ratio HR 0.69, 95% CI 0.52-0.93). In contrast, no significant differences were observed between patients receiving denosumab and those receiving bisphosphonates in terms of 5-year TSA incidence (1.8% vs 1.4%, p = 0.561) or on Kaplan-Meier analysis (HR 1.25, 95% CI 0.58-2.67). CONCLUSION: OP medications in patients with shoulder OA were associated with a reduced incidence of TSA. No differences were observed between denosumab and bisphosphonates. These findings suggest a potential role for antiresorptive therapy in delaying progression of shoulder OA.
引用
- Haj Shehadeh T, El Zeini M, Elzomor T, et al. Decreased incidence of shoulder arthroplasty in patients prescribed anti-resorptive therapy for osteoporosis. Osteoporos Int. 2026. PMID: 42809099. doi:10.1007/s00198-026-08229-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。